Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2151576 | 0.89 | DUT (0.36) | DUT | |
| SCHEMBL7698447 | 0.86 | CYP4F2 (0.33) | DUT | |
| SCHEMBL2883658 | 0.85 | DUT (0.31) | DUT | |
| SCHEMBL4053298 | 0.81 | — | — | |
| SCHEMBL30378311 | 0.80 | — | — | |
| SCHEMBL738264 | 0.80 | DUT (0.34) | DUT | |
| SCHEMBL2151865 | 0.78 | DUT (0.32) | DUT | |
| SCHEMBL29132502 | 0.76 | LMNA (0.37) | DUT | |
| SCHEMBL571057 | 0.76 | DUT (0.39) | DUT | |
| SCHEMBL1314515 | 0.75 | DUT (0.34) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2025132542-A1 | MACROCYCLIC OREXIN AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-26 | — | — | WO | disclosed |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. | 2025-03-06 | — | — | US | disclosed |
| WO-2022159644-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| CN-111491623-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| WO-2019079357-A1 | TNIK MODULATORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8288431-B2 | Substituted spiroindolinones | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| WO-2012007409-A1 | N-SUBSTITUTED PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010235-A1 | N-SUBSTITUTED PYRROLIDINES | CHU XIN-JIE (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2011101297-A1 | SUBSTITUTED SPIROINDOLINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011098398-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-18 | — | — | WO | disclosed |
| US-20110201635-A1 | SUBSTITUTED SPIROINDOLINONES | LIU JIN-JUN | 2011-08-18 | — | — | US | disclosed |
| EP-2340021-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2011-07-06 | — | — | EP | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
| WO-2010031713-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | DING QINGJIE | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010235-A1 | N-SUBSTITUTED PYRROLIDINES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PKD1, TP53 | DUT 321/4885 |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | DUT 1184/4885 |
| US-20110201635-A1 | SUBSTITUTED SPIROINDOLINONES | CCNY, XPOT, FOXK1 | DUT 1433/4885 |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | FOXM1, MDM2, FOXO1 | DUT 3342/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | DUT 2554/4885 |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | DUT 1184/4885 |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | DUT 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.